Učitavanje...

SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have been used as the first‐line treatment of non‐small cell lung cancers (NSCLC) harboring EGFR‐activating mutations, but acquired resistance is ubiquitous and needs to be solved urgently. Here, we introduce an effective appro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Sci
Glavni autori: Tong, Mengya, Gao, Mingzhao, Xu, Yongping, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Quan, Haitian, Lou, Liguang
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825016/
https://ncbi.nlm.nih.gov/pubmed/31446643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14180
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!